An in-depth analysis of patient-reported outcomes in patients with chronic Hepatitis C treated with different anti-viral regimens

American Journal of Gastroenterology

Volumn 111, Issue 6, 2016, Pages 808-816

  Younossi, Zobair M ^a,b   Stepanova, Maria ^c   Henry, Linda ^c   Nader, Fatema ^c   Hunt, Sharon ^c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE QUESTIONNAIRE HEPATITIS C VIRUS; CONTROLLED STUDY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE AND FATIGUE SPECIFIC QUESTIONNAIRE; GASTROINTESTINAL SYMPTOM; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; LIVER CIRRHOSIS; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PATIENT REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SHORT FORM 36; SKIN DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WP AND ACTIVITY IMPAIRMEN SPECIFIC HEALTH PROBLEM QUESTIONNAIRE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MULTICENTER STUDY; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; RETROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR;

EID: 84961891957     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.99     Document Type: Article

References (40)

1. Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014; 39: 518-31.
2. Gnanasakthy A, Mordin M, Clark M, et al. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health 2012; 15: 437-42.
3. Centers for Disease Control-Health Related Quality of Life. Obtained from http://www.cdc.gov/HRQoL/concept.htm Last accessed on 13 October 2015.
4. van der Plas SM, Hansen BE, de Boer JB, et al. Generic and disease-specifi c health related quality of life of liver patients with various aetiologies: a survey. Qual Life Res 2007; 16: 375-88.
5. The health measurement research group. Health related quality of life tools. Obtained from http://www.healthmeasurement.org/Measures.html Last accessed on 13 October 2015.
6. Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.
7. Kallman J, O'Neil MM, Larive B, et al. Fatigue and health-related quality of life (HRQOL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52: 2531-9.
8. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-81.
9. Boscarino JA, Lu M, Moorman AC, et al. Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: The chronic hepatitis cohort study (CHeCS). Hepatology 2015; 61: 802-11.
10. Afendy A, Kallman JB, Stepanova M, et al. Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther 2009; 30: 469-76.
11. Gerber L, Estep M, Stepanova M, et al. Eff ects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2016; 14: 156-64. e3.
12. Sobhonslidsuk A, Silpakit C, Kongsakon R, et al. Factors infl uencing health-related quality of life in chronic liver disease. World J Gastroenterol 2006; 12: 7786-91.
13. Gutteling JJ, de Man RA, van der Plas SM, et al. Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 2006; 23: 1629-35.
14. DiBonaventura M, Wagner JS, Yuan Y, et al. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 2011; 14: 253-61.
15. Su J, Brook RA, Kleinman NL, et al. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefi t costs. Hepatology 2010; 52: 436-42.
16. Mchutchison JG, Ware JE, Bayliss MS, et al. The Eff ects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 34 ( 1 ): 2001, 140-7.
17. Brook RA, Kleinman NL, Su J, et al. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care 2011; 17: 657-64.
18. John-Baptiste AA, Tomlinson G, Hsu PC, et al. Sustained responders have better quality of life and productivity compared with treatment failures long aft er antiviral therapy for hepatitis C. Am J Gastroenterol 2009; 104: 2439-48.
19. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C-The impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015; 41: 497-520.
20. Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014; 60: 741-7.
21. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014; 46 ( Suppl 5 ): S186-96.
22. Younossi ZM, Stepanova M, Henry L, et al. Eff ects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014; 12: 1349-59. e13
23. Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis 2015; 212: 367-77.
24. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 2015; 61: 1798-808.
25. Redelmeier DA, Dickinson VM. Determining whether a patient is feeling better: pitfalls from the science of human perception. J Gen Intern Med 2011; 26: 900-6.
26. Younossi ZM, Stepanova M, Nader F, et al. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- And ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther 2015; 42: 286-95.
27. Zeuzem S, Dusheiko G, Salupere R, et al. Sofosbuvir+ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013; 58: 1085.
28. Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15: 397-404.
29. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
30. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
31. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
32. Younossi ZM, Stepanova M, Zeuzem S, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 2014; 61: 228-34.
33. Webster K, Odom L, Peterman A, et al. The Functional assessment of chronic illness therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res 1999; 8: 604.
34. Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specifi c questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45: 295-300.
35. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001; 10: 405-13.
36. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65.
37. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015; 63: 337-45.
38. Younossi ZM, Jiang Y, Smith NJ, et al. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology 2015; 61: 1471-8.
39. Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefi ts. BMC Infect Dis 2015; 15: 19.
40. Younossi ZM, Park H, Saab S, et al. Cost-eff ectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015; 41: 544-63.